Camidge R, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). IASLC 2018, abstract PL02.03.
Rookvrije toekomst kan in 22 jaar ten minste 120.000 kankerdiagnoses voorkomen
okt 2024 | Longoncologie, Maag-darm-leveroncologie, Uro-oncologie